Literature DB >> 20097046

Outcomes of 1014 naturalistically treated inpatients with major depressive episode.

Florian Seemüller1, Michael Riedel, Michael Obermeier, Michael Bauer, Mazda Adli, Klaus Kronmüller, Florian Holsboer, Peter Brieger, Gerd Laux, Wolfram Bender, Isabella Heuser, Joachim Zeiler, Wolfgang Gaebel, Eva Dichgans, Roland Bottländer, Richard Musil, Hans-Jürgen Möller.   

Abstract

Due to strict exclusion criteria the generalizability of randomized controlled trials appears to be limited. Therefore, outcomes of naturalistically treated depressive inpatients with respect to depression mean scores, response and remission rates were evaluated. This was a multicenter trial, conducted in 12 psychiatric hospitals in Germany with a follow-up period of 4years. Patients were assessed biweekly from admission to discharge with diverse psychopathological rating scales. All patients (n=1014) met DSM-IV criteria for major depressive episode. Results are presented only for the acute inpatient treatment period. Mean inpatient treatment duration was 53.6+/-47.5days. Reduction on depression scales was evident as soon as week 2 and remained significant. Mean HAMD-17 total score decreased from 22.3 to 8.8. A total of 68.9% were classified as responders (> or =50% reduction of the initial HAMD-17 score), whereas 51.9% achieved remission (HAMD-17 total score < or =7). Of those who ultimately achieved response more than 40% did so within the first 2weeks. An individualized naturalistic inpatient treatment approach appears to be beneficial in terms of effectiveness. 2009 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20097046     DOI: 10.1016/j.euroneuro.2009.11.011

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  24 in total

1.  Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors.

Authors:  Florian Seemüller; Sebastian Meier; Michael Obermeier; Richard Musil; Michael Bauer; Mazda Adli; Klaus Kronmüller; Florian Holsboer; Peter Brieger; Gerd Laux; Wolfram Bender; Isabella Heuser; Joachim Zeiler; Wolfgang Gaebel; Michael Riedel; Peter Falkai; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-03-04       Impact factor: 5.270

2.  General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11       Impact factor: 5.270

3.  Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder.

Authors:  Richard Musil; Florian Seemüller; Sebastian Meyer; Ilja Spellmann; Mazda Adli; Michael Bauer; Klaus-Thomas Kronmüller; Peter Brieger; Gerd Laux; Wolfram Bender; Isabella Heuser; Robert Fisher; Wolfgang Gaebel; Rebecca Schennach; Hans-Jürgen Möller; Michael Riedel
Journal:  Int J Methods Psychiatr Res       Date:  2017-06-14       Impact factor: 4.035

4.  Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan J Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-15       Impact factor: 5.270

5.  Is the Ultimate Treatment Response Predictable with Early Response in Major Depressive Episode?

Authors:  Aslı Çiftçi; Halis Ulaş; Ahmet Topuzoğlu; Zeliha Tunca
Journal:  Noro Psikiyatr Ars       Date:  2016-09-01       Impact factor: 1.339

6.  Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium.

Authors:  Eline Vandael; Thomas Marynissen; Johan Reyntens; Isabel Spriet; Joris Vandenberghe; Rik Willems; Veerle Foulon
Journal:  Int J Clin Pharm       Date:  2014-05-08

7.  Treatment patterns in inpatient depression care.

Authors:  Alessa von Wolff; Ramona Meister; Martin Härter; Levente Kriston
Journal:  Int J Methods Psychiatr Res       Date:  2015-08-18       Impact factor: 4.035

8.  The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder.

Authors:  Steven J Garlow; Boadie W Dunlop; Philip T Ninan; Charles B Nemeroff
Journal:  J Psychiatr Res       Date:  2012-09-07       Impact factor: 4.791

9.  No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression.

Authors:  Richard Musil; Peter Zill; Florian Seemüller; Brigitta Bondy; Michael Obermeier; Ilja Spellmann; Wolfram Bender; Mazda Adli; Isabella Heuser; Joachim Zeiler; Wolfgang Gaebel; Wolfgang Maier; Marcella Rietschel; Dan Rujescu; Rebecca Schennach; Hans-Jürgen Möller; Michael Riedel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-09-11       Impact factor: 5.270

10.  The relationship of health-related quality of life and treatment outcome during inpatient treatment of depression.

Authors:  Stephan Köhler; Theresa Unger; Sabine Hoffmann; Arthur Mackert; Barbara Ross; Thomas Fydrich
Journal:  Qual Life Res       Date:  2014-09-21       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.